Nutriband Inc
NTRB
View Detailed Chart
4.780USD
-0.260-5.16%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
52.94MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.16%
5 Days
-13.09%
1 Month
-34.30%
6 Months
-10.82%
Year to Date
+1.49%
1 Year
-3.24%
View Detailed Chart
TradingKey Stock Score of Nutriband Inc
Currency: USD Updated: 2025-11-21Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nutriband Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
15.000
Target Price
+197.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Nutriband Inc Highlights
StrengthsRisks
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.14M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.14M.
Overvalued
The company’s latest PE is -1.66, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 350.65K shares, decreasing 16.90% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 202.74K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.68.
Nutriband Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nutriband Inc Info
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Ticker SymbolNTRB
CompanyNutriband Inc
CEOMr. Serguei Melnik
Websitehttps://nutriband.com/
FAQs
What is the current price of Nutriband Inc (NTRB)?
The current price of Nutriband Inc (NTRB) is 4.780.
What is the symbol of Nutriband Inc?
The ticker symbol of Nutriband Inc is NTRB.
What is the 52-week high of Nutriband Inc?
The 52-week high of Nutriband Inc is 11.780.
What is the 52-week low of Nutriband Inc?
The 52-week low of Nutriband Inc is 3.722.
What is the market capitalization of Nutriband Inc?
The market capitalization of Nutriband Inc is 52.94M.
What is the net income of Nutriband Inc?
The net income of Nutriband Inc is -5.49M.
Is Nutriband Inc (NTRB) currently rated as Buy, Hold, or Sell?
According to analysts, Nutriband Inc (NTRB) has an overall rating of Buy, with a price target of 15.000.
What is the Earnings Per Share (EPS TTM) of Nutriband Inc (NTRB)?
The Earnings Per Share (EPS TTM) of Nutriband Inc (NTRB) is -0.615.
Related Instruments
+2.71%
+3.34%
+2.57%
+1.70%
+2.34%
+0.29%
+2.16%
+1.86%
+3.09%
+2.62%
+3.15%
+2.47%
+1.00%
+5.30%
+1.66%
+1.24%
+4.27%
-9.77%
+2.08%
+2.80%
